Teva Pharma (TEVA) - A History of Takeovers

Teva Pharmaceutical Industries (NASDAQ: TEVA) said on Thursday it would acquire Germany's Ratiopharm for $4.95 billion, including debt.

It's unusual for an acquirer’s stock to go up after announcing a takeover but Teva has a history of smart takeovers. Teva's stock is presently up 3%.

Here are the major acquisitions by Teva, Israel's largest company and the world's biggest maker of generic drugs:

In December 2008, Teva bought Barr Pharmaceuticals in the U.S. and its European subsidiary Pliva for $7.5 billion. It was the largest acquisition in Teva's history. The deal enhanced Teva's leadership position in the U.S. generic drugs market and strengthened its position in Europe.

Teva acquired U.S.-based IVAX Corp in 2006 for $7.4 billion, bringing it a strong presence in Latin America and Central and Eastern Europe. IVAX had a significant presence in the respiratory business and oncology.

In January 2004. Teva paid $3.4 billion for Sicor, which had a leading generic injectable business as well as biogeneric.

In 2000, Teva bought privately held Novopharm, Canada's second-largest generic company, making Teva the largest generic drug company in North America. Novopharm's primary business was generic drugs. Their other lines ncluded sterile products, vitamins and over-the-counter products.

In August 1999, Teva bought Massachusetts-based Copley Pharmaceutical Inc, a maker of generic and branded drugs, for $220 million.